Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pepcid AC garners leading share of antacid market since June launch -- J&J/Merck.

This article was originally published in The Tan Sheet

Executive Summary

PEPCID AC SHARE OF HEARTBURN CATEGORY PEGGED AT OVER 20% by Johnson & Johnson/Merck. The company said in a Sept. 5 legal document that Pepcid AC has captured more than 20% of the $800 mil. "heartburn relief" category in "recent weeks." J&J/Merck launched the Rx-to-OTC switch H2 antagonist in June ("The Tan Sheet" June 12, p. 3).
Advertisement

Related Content

Singulair Switch Among Merck's OTC Possibilities
Singulair Switch Among Merck's OTC Possibilities
Singulair Switch Among Merck's OTC Possibilities

Topics

Advertisement
UsernamePublicRestriction

Register

PS084281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel